
October - December 2024 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event ...
Alecensa (alectinib) capsules Alunbrig (brigatinib) tablets Lorbrena (lorlatinib) tablets Zykadia (ceritinib) capsules; tablets Optic neuropathy FDA is evaluating the need for regulatory action. Antidepressants Selective serotonin reuptake inhibitors ( …